GeneCentric Therapeutics at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

GeneCentric Therapeutics at ASHG 2026 in Montréal: 1 presentation (1 platform talk).

Organization	ASHG 2026 Attendance
GeneCentric Therapeutics Chapel Hill, North Carolina	1 bioinformatics scientist
genecentric.com\|LinkedIn Private company GeneCentric commercializes its technology through strategic collaborations with biopharmaceutical and diagnostics companies in applications throughout preclinical testing, clinical drug development, and commercialization lifecycle phases. Launched ExpressCT Rewind, a service that applies its fragmentomics pipeline to existing DNA sequencing data retrospectively. › Launched ExpressCT Rewind, a service that applies its fragmentomics pipeline to existing DNA sequencing data retrospectively. 2026-07 · source Presented three posters on its fragmentomics-based ExpressCT liquid-biopsy technology at the AACR 2026 meeting. 2026-04 · source Its PurIST algorithm was validated in a Tempus study for improving pancreatic-cancer therapy selection. 2025-09 · source Source: company newsroom $8.0M Series C led by Hatteras Venture Partners (Jun 2025) › An initial closing of the round; full round size may grow beyond $8.0 million. · 2025-06-18 “GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing.” Source: funding announcement Currently hiring: 1 open roles › Source: careers page	Talk Fri Oct 23 11:45 am Part of Single-Cell, Multi-Omics, and Liquid Biopsy Approaches to Decode Lung Disease Genetics and Biomarkers Beneath the variants: Fragmentomics unmasks epigenomic signal from existing mutation profiling of cfDNA for lung cancer classification and prognosis Room 516BC/Level 5 BioinformaticsCancerDiagnosticsEpigenetics

Organization

ASHG 2026 Attendance

GeneCentric Therapeutics

Chapel Hill, North Carolina

1 bioinformatics scientist

genecentric.com|LinkedIn

Private company

GeneCentric commercializes its technology through strategic collaborations with biopharmaceutical and diagnostics companies in applications throughout preclinical testing, clinical drug development, and commercialization lifecycle phases.

Launched ExpressCT Rewind, a service that applies its fragmentomics pipeline to existing DNA sequencing data retrospectively.

›

Launched ExpressCT Rewind, a service that applies its fragmentomics pipeline to existing DNA sequencing data retrospectively.

2026-07 · source

Presented three posters on its fragmentomics-based ExpressCT liquid-biopsy technology at the AACR 2026 meeting.

2026-04 · source

Its PurIST algorithm was validated in a Tempus study for improving pancreatic-cancer therapy selection.

2025-09 · source

Source: company newsroom

$8.0M Series C led by Hatteras Venture Partners (Jun 2025)

›

An initial closing of the round; full round size may grow beyond $8.0 million. · 2025-06-18

“GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing.”

Source: funding announcement

Currently hiring: 1 open roles

›

Source: careers page

Talk

Fri Oct 23
11:45 am

Part of Single-Cell, Multi-Omics, and Liquid Biopsy Approaches to Decode Lung Disease Genetics and Biomarkers

Beneath the variants: Fragmentomics unmasks epigenomic signal from existing mutation profiling of cfDNA for lung cancer classification and prognosis

Room 516BC/Level 5

BioinformaticsCancerDiagnosticsEpigenetics